Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. The GSK executives are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback